Long non-coding RNAs as the critical factors during tumor progressions among Iranian population: an overview

Rahmani, Zahra; Mojarrad, Majid; Moghbeli, Meysam

doi:10.1186/s13578-020-0373-0

Cited by 31 publications

(16 citation statements)

References 142 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, low efficiency of conventional treatments highlights the importance of effective tumor-specific therapeutic strategies [1]. Non-coding RNAs (ncRNAs) are important post-transcriptional regulators that affect cell apoptosis, proliferation, and differentiation [2][3][4]. MiRNAs are a group of short ncRNAs (19-24 nucleotides) that target mRNAs using binding with the 3′-untranslated region (UTR), resulting in mRNA degradation and translational suppression [5].…”

mentioning

confidence: 99%

Molecular interactions of miR-338 during tumor progression and metastasis

Moghbeli

2021

Cell Mol Biol Lett

Self Cite

View full text Add to dashboard Cite

Background Cancer, as one of the main causes of human deaths, is currently a significant global health challenge. Since the majority of cancer-related deaths are associated with late diagnosis, it is necessary to develop minimally invasive early detection markers to manage and reduce mortality rates. MicroRNAs (miRNAs), as highly conserved non-coding RNAs, target the specific mRNAs which are involved in regulation of various fundamental cellular processes such as cell proliferation, death, and signaling pathways. MiRNAs can also be regulated by long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs). They are highly stable in body fluids and have tumor-specific expression profiles, which suggest their suitability as efficient non-invasive diagnostic and prognostic tumor markers. Aberrant expression of miR-338 has been widely reported in different cancers. It regulates cell proliferation, migration, angiogenesis, and apoptosis in tumor cells. Main body In the present review, we have summarized all miR-338 interactions with other non-coding RNAs (ncRNAs) and associated signaling pathways to clarify the role of miR-338 during tumor progression. Conclusions It was concluded that miR-338 mainly functions as a tumor suppressor in different cancers. There were also significant associations between miR-338 and other ncRNAs in tumor cells. Moreover, miR-338 has a pivotal role during tumor progression using the regulation of WNT, MAPK, and PI3K/AKT signaling pathways. This review highlights miR-338 as a pivotal ncRNA in biology of tumor cells.

show abstract

mentioning

confidence: 99%

Molecular interactions of miR-338 during tumor progression and metastasis

Moghbeli

2021

Cell Mol Biol Lett

Self Cite

View full text Add to dashboard Cite

show abstract

“…The role of lncRNA as potential powerful biomarker has been reported in several cancers, including CRC (Chi et al, 2019 ; Pichler et al, 2020 ; Rahmani et al, 2020 ; Wang et al, 2020 ; Wu et al, 2020 ). In previous studies, lncRNAs can act as the biomarker for diagnosis and prediction of the prognosis and progression in CRC patients (Alidoust et al, 2018 ; Wei et al, 2019 ; Pichler et al, 2020 ).…”

Section: Discussionmentioning

confidence: 99%

Identification of LncRNAs Associated With FOLFOX Chemoresistance in mCRC and Construction of a Predictive Model

Zhang

Sun

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Oxaliplatin, fluorouracil plus leucovorin (FOLFOX) regimen is the first-line chemotherapy of patients with metastatic colorectal cancer (mCRC). However, studies are limited regarding long non-coding RNAs (lncRNAs) associated with FOLFOX chemotherapy response and prognosis. This study aimed to identify lncRNAs associated with FOLFOX chemotherapy response and prognosis in mCRC patients and to construct a predictive model. We analyzed lncRNA expression in 11 mCRC patients treated with FOLFOX chemotherapy before surgery (four sensitive, seven resistant) by Gene Array Chip. The top eight lncRNAs (AC007193.8, CTD-2008N3.1, FLJ36777, RP11-509J21.4, RP3-508I15.20, LOC100130950, RP5-1042K10.13, and LINC00476) for chemotherapy response were identified according to weighted correlation network analysis (WGCNA). A competitive endogenous RNA (ceRNA) network was then constructed. The crucial functions of the eight lncRNAs enriched in chemotherapy resistance were mitogen-activated protein kinase (MAPK) and proteoglycans signaling pathway. Receiver operating characteristic (ROC) analysis demonstrated that the eight lncRNAs were potent predictors for chemotherapy resistance of mCRC patients. To further identify a signature model lncRNA chemotherapy response and prognosis, the validation set consisted of 196 CRC patients from our center was used to validate lncRNAs expression and prognosis by quantitative PCR (qPCR). The expression of the eight lncRNAs expression between CRC cancerous and adjacent non-cancerous tissues was also verified in the validation data set to determine the prognostic value. A generalized linear model was established to predict the probability of chemotherapy resistance and survival. Our findings showed that the eight-lncRNA signature may be a novel biomarker for the prediction of FOLFOX chemotherapy response and prognosis of mCRC patients.

show abstract

“…LncRNAs have important effects on tumorigenesis through their modulation of various pathophysiological processes, including the stability of mRNA, RNA splicing, chromatin remodeling and miRNA sponging (Fig. 1 ) [ 21 – 26 ]. Their deregulation is one of the main obstacles for the effectiveness of chemotherapy [ 27 – 29 ].…”

Section: Introductionmentioning

confidence: 99%

Long non-coding RNAs as the critical regulators of doxorubicin resistance in tumor cells

Khalili-Tanha

Moghbeli

2021

Cell Mol Biol Lett

Self Cite

View full text Add to dashboard Cite

Resistance against conventional chemotherapeutic agents is one of the main reasons for tumor relapse and poor clinical outcomes in cancer patients. Various mechanisms are associated with drug resistance, including drug efflux, cell cycle, DNA repair and apoptosis. Doxorubicin (DOX) is a widely used first-line anti-cancer drug that functions as a DNA topoisomerase II inhibitor. However, DOX resistance has emerged as a large hurdle in efficient tumor therapy. Furthermore, despite its wide clinical application, DOX is a double-edged sword: it can damage normal tissues and affect the quality of patients’ lives during and after treatment. It is essential to clarify the molecular basis of DOX resistance to support the development of novel therapeutic modalities with fewer and/or lower-impact side effects in cancer patients. Long non-coding RNAs (lncRNAs) have critical roles in the drug resistance of various tumors. In this review, we summarize the state of knowledge on all the lncRNAs associated with DOX resistance. The majority are involved in promoting DOX resistance. This review paves the way to introducing an lncRNA panel marker for the prediction of the DOX response and clinical outcomes for cancer patients.

show abstract

Long non-coding RNAs as the critical factors during tumor progressions among Iranian population: an overview

Cited by 31 publications

References 142 publications

Molecular interactions of miR-338 during tumor progression and metastasis

Molecular interactions of miR-338 during tumor progression and metastasis

Identification of LncRNAs Associated With FOLFOX Chemoresistance in mCRC and Construction of a Predictive Model

Long non-coding RNAs as the critical regulators of doxorubicin resistance in tumor cells

Contact Info

Product

Resources

About